SARS CoV-2 Infection Clinical Trial
Official title:
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to reduce inflammation and fibrosis in patients with a variety of medical conditions. The investigators hypothesize that using nebulized and/or intravenous purified (acellular) amniotic fluid will reduce both inflammation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05036941 -
A Trial of Two Mask Systems in Preventing SARS CoV-2 in Healthcare Workers (HCW)
|
N/A | |
| Terminated |
NCT04748783 -
Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19
|
Phase 2 | |
| Recruiting |
NCT05587868 -
COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients
|
||
| Completed |
NCT05598957 -
Evaluation of the Relationship of Vitamin D and Vitamin D Binding Protein With Disease Severity in Pediatric Sars-CoV2
|
||
| Active, not recruiting |
NCT04756466 -
Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly
|
N/A |